These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 37000363)

  • 21. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States.
    Long MD; Smith TW; Dibonaventura M; Gruben D; Bargo D; Salese L; Quirk D
    Inflamm Bowel Dis; 2020 May; 26(6):941-948. PubMed ID: 31560046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis.
    Jordan RE; Majothi S; Heneghan NR; Blissett DB; Riley RD; Sitch AJ; Price MJ; Bates EJ; Turner AM; Bayliss S; Moore D; Singh S; Adab P; Fitzmaurice DA; Jowett S; Jolly K
    Health Technol Assess; 2015 May; 19(36):1-516. PubMed ID: 25980984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review.
    Witkowski M; Moreno SI; Fernandes J; Johansen P; Augusto M; Nair S
    Pharmacoeconomics; 2022 Aug; 40(8):751-776. PubMed ID: 35789987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.
    Cohen R; Skup M; Ozbay AB; Rizzo J; Yang M; Diener M; Chao J
    J Med Econ; 2015 Jun; 18(6):447-56. PubMed ID: 25728698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effectiveness and cost-effectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers.
    Bajwah S; Oluyase AO; Yi D; Gao W; Evans CJ; Grande G; Todd C; Costantini M; Murtagh FE; Higginson IJ
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012780. PubMed ID: 32996586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Prescription Pattern and Healthcare Cost Among Patients with Ulcerative Colitis in Japan: A Retrospective Claims Data Analysis.
    Miyazaki C; Sakashita T; Jung W; Kato S
    Adv Ther; 2021 May; 38(5):2229-2247. PubMed ID: 33515423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of biological agents used in ulcerative colitis.
    Lee JK; Tang DH; Mollon L; Armstrong EP
    Best Pract Res Clin Gastroenterol; 2013 Dec; 27(6):949-60. PubMed ID: 24182613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
    Bonovas S; Lytras T; Nikolopoulos G; Peyrin-Biroulet L; Danese S
    Aliment Pharmacol Ther; 2018 Feb; 47(4):454-465. PubMed ID: 29205421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe.
    Ruiz-Casas L; Evans J; Rose A; Pedra GG; Lobo A; Finnegan A; Hayee B; Peyrin-Biroulet L; Sturm A; Burisch J; Terry H; Avedano L; Tucknott S; Fiorino G; Limdi J
    BMC Gastroenterol; 2021 Dec; 21(1):456. PubMed ID: 34863112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population.
    Pilon D; Ding Z; Muser E; Obando C; Voelker J; Manceur AM; Kinkead F; Lafeuille MH; Lefebvre P
    Curr Med Res Opin; 2020 Aug; 36(8):1285-1294. PubMed ID: 32427006
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis.
    Long MD; Cohen RD; Smith TW; DiBonaventura M; Gruben D; Bargo D; Salese L; Quirk D
    Dig Dis; 2022; 40(5):553-564. PubMed ID: 34879378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cost burden of Crohn's disease and ulcerative colitis depending on biologic treatment status - a Danish register-based study.
    Alulis S; Vadstrup K; Olsen J; Jørgensen TR; Qvist N; Munkholm P; Borsi A
    BMC Health Serv Res; 2021 Aug; 21(1):836. PubMed ID: 34407821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Efficacy of Biologics and Small Molecule Therapies in Improving Patient-Reported Outcomes in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
    Shehab M; Hassan A; Alrashed F; Abbas A; Ma C; Narula N; Jairath V; Singh S; Bessissow T
    Inflamm Bowel Dis; 2024 Aug; ():. PubMed ID: 39137239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis.
    Brookes MJ; Waller J; Cappelleri JC; Modesto I; DiBonaventura MD; Bohm N; Mokgokong R; Massey O; Wood R; Bargo D
    BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32938582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil.
    Parra RS; Chebli JMF; Amarante HMBS; Flores C; Parente JML; Ramos O; Fernandes M; Rocha JJR; Feitosa MR; Feres O; Scotton AS; Nones RB; Lima MM; Zaltman C; Goncalves CD; Guimaraes IM; Santana GO; Sassaki LY; Hossne RS; Bafutto M; Junior RLK; Faria MAG; Miszputen SJ; Gomes TNF; Catapani WR; Faria AA; Souza SCS; Caratin RF; Senra JT; Ferrari MLA
    World J Gastroenterol; 2019 Oct; 25(38):5862-5882. PubMed ID: 31636478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic review: the financial burden of surgical complications in patients with ulcerative colitis.
    Lindsay JO; Bergman A; Patel AS; Alesso SM; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2015 Jun; 41(11):1066-78. PubMed ID: 25855078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review.
    Hillhouse E; Mathurin K; Bibeau J; Parison D; Rahal Y; Lachaine J; Beauchemin C
    Adv Ther; 2022 Jan; 39(1):455-487. PubMed ID: 34780028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclosporine A for induction of remission in severe ulcerative colitis.
    Shibolet O; Regushevskaya E; Brezis M; Soares-Weiser K
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004277. PubMed ID: 15674937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.